Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 27460442

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2016 Sep
First author
Brose MS

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Sep;17(9):1181-3. doi: 10.1016/S1470-2045(16)30230-3.
    note
    Source null
    related pmid
    27460441
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2016 Nov;17(11):e468. doi: 10.1016/S1470-2045(16)30499-5.
    note
    Source null
    related pmid
    27819235
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2016 Nov;17(11):e469. doi: 10.1016/S1470-2045(16)30520-4.
    note
    Source null
    related pmid
    27819236
    relationship
    Comment in

Authors and identifiers

  1. name
    Brose MS
    type
    Author
  2. name
    Cabanillas ME
    type
    Author
  3. name
    Cohen EE
    type
    Author
  4. name
    Wirth LJ
    type
    Author
  5. name
    Riehl T
    type
    Author
  6. name
    Yue H
    type
    Author
  7. name
    Sherman SI
    type
    Author
  8. name
    Sherman EJ
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Brose MS
    type
    Author
  2. name
    Cabanillas ME
    type
    Author
  3. name
    Cohen EE
    type
    Author
  4. name
    Wirth LJ
    type
    Author
  5. name
    Riehl T
    type
    Author
  6. name
    Yue H
    type
    Author
  7. name
    Sherman SI
    type
    Author
  8. name
    Sherman EJ
    type
    Author
bibliography ids
  1. nci-bib-ed1a313296492320c03f9852
book metadata
content sha256
62dced169040b3699f6d1b82fb2791005920e504dcd0688c920ba2cac3a3d11a
document type
citation
dois
  1. 10.1016/S1470-2045(16)30166-8
electronic publication date
display
2016 Jul 23
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27460442
immutable id
pubmed:27460442@62dced169040b3699f6d1b82fb2791005920e504dcd0688c920ba2cac3a3d11a
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
9
name
The Lancet. Oncology
nlm unique id
100957246
pages
1272-82
volume
17
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Sep;17(9):1181-3. doi: 10.1016/S1470-2045(16)30230-3.
    note
    Source null
    related pmid
    27460441
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2016 Nov;17(11):e468. doi: 10.1016/S1470-2045(16)30499-5.
    note
    Source null
    related pmid
    27819235
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2016 Nov;17(11):e469. doi: 10.1016/S1470-2045(16)30520-4.
    note
    Source null
    related pmid
    27819236
    relationship
    Comment in
outcomes validated
false
pmid
27460442
provenance
batch id
d649bcb2d98dbbacd53c
provider
NCBI PubMed ESummary
record sha256
b52691437a7b3bffdc7376b0915a705860121cc19f131d4de095d1f3f76a72c6
response sha256
26648a40f123f366675007f51cc29befd1f9a89273ca2da87c477c54d2d15d20
retrieved at
2026-09-09T23:47:20.761544+00:00
publication date
display
2016 Sep
precision
month
year
2016
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27460442/
title
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

Preserved source evidence · Not medical advice